Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.38 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432578 | 0.91 | KLKB1 (0.39) | MAPK14KMT2APLGPRSS1PRSS2 | |
| SCHEMBL1432254 | 0.91 | KLKB1 (0.39) | MAPK14KMT2APLGPRSS1PRSS2 | |
| SCHEMBL3149782 | 0.91 | KLKB1 (0.39) | MAPK14KMT2APLGPRSS1PRSS2 | |
| SCHEMBL1432414 | 0.88 | CTSL (0.44) | CTSLKLKB1 | |
| SCHEMBL3149564 | 0.88 | F2 (0.45) | MAPK14F2CTSLCCR2KDM4E | |
| SCHEMBL3149571 | 0.88 | F2 (0.45) | MAPK14F2CTSLCCR2KDM4E | |
| SCHEMBL1432560 | 0.86 | EHMT2 (0.41) | KMT2AFURINMASP2KLKB1 | |
| SCHEMBL1432137 | 0.85 | EHMT2 (0.44) | KMT2AFURINMASP2KLKB1 | |
| SCHEMBL3144759 | 0.85 | PDPK1 (0.41) | KMT2AFURINMASP2KLKB1 | |
| SCHEMBL3144731 | 0.85 | PDPK1 (0.41) | KMT2AFURINMASP2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MAPK14 2952/4885F2 1046/4885CTSL 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.